00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
07:00 , Jul 15, 2013 |  BioCentury  |  Strategy

Triple advantage in COPD

AstraZeneca plc 's acquisition of Pearl Therapeutics Inc. gives the pharma an entry point into the LAMA/LABA race and a platform to build out other combination products. While the Pearl programs may be a couple...